Une expertise pluridisciplinaire au service de la santé publique
Haut Conseil de la santé publique
Le Haut Conseil de la santé publique vous souhaite une excellente année 2022

Vous êtes ici :

Maintaining safe donations of blood, cells, tissue and organs while SARS-CoV-2 is actively circulating

On 11 March, the World Health Organization characterised COVID-19 as a pandemic. France is now at stage 3 of the epidemic. In this context, maintaining safe products of the human body is a priority. With respect to labile blood products (LBPs), this means ensuring safety for the recipient, donor and clinic staff whilst maintaining supplies to ensure LBP self-sufficiency.

Taking into account, following the example of WHO and the ECDC, an assessment that considers as purely theoretical the risk of SARS-CoV-2 being transfusion-transmissible, a treatment inactivating the virus for platelets and a safe quarantine of plasma, the French High Council for Public Health (Haut Conseil de la santé publique, HCSP) recommends, at stage 3 of the epidemic, excluding anyone with possible direct exposure to COVID-19 from a confirmed case, as well as symptomatic individuals, from blood donations for 28 days, and improving pre- and post-donation information.

Nucleic acid testing for the virus is not recommended as this is impracticable in practice.

With respect to tissue and organ transplants, the HCSP recommends screening for SARS-CoV-2 by RT-PCR assay on a nasopharyngeal swab for any living donor. Where the donor is deceased, action should be based on the availability of results of tests prior to the transplant; where such results are unavailable, only vital organs (heart, liver), may be transplanted and the recipient must have been informed of this situation.
The HCSP has issued two statements: one dated 7 February and amended on 24 February 2020, and the other dated 14 March, adapting the recommendations to the epidemiological situation.

Lire en français :

Veuillez patienter quelques instants...